@article{TCR10086,
author = {Jiabin Zheng and Junjiang Wang and Xingyu Feng and Yong Li},
title = {A systematic review and meta-analysis of the efficacy and safety of long-acting release somatostatin analogs in patients with advanced neuroendocrine neoplasms},
journal = {Translational Cancer Research},
volume = {5},
number = {5},
year = {2016},
keywords = {},
abstract = {Background: Because the morbidity of neuroendocrine neoplasms (NENs) increases each year, clinical trials are increasingly exploring treatment options to control tumor growth. These trials have revealed that long-acting release (LAR) somatostatin analogs (SSAs) are effective therapies. The objective for this article is to perform a meta-analysis to assess the efficiency and safety of SSAs in delaying NEN progress.
Methods: To identify clinical trials of SSAs in NENs published until May 2016, we searched PubMed, the Cochrane Library and the CBM databases by combining various key words. Both retrospective and prospective studies were included. Data were extracted from every study to perform a meta-analysis using RevMan 5.3 software.
Results: Seven studies consisting of two randomized control trial (RCTs), one non-RCT and four single-arm studies with a total of 788 patients were included. The pooled hazard ratio (HR) for progression-free survival/time to progression (PFS/TTP) was 0.43 (95% CI: 0.36–0.51, P},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/10086}
}